Haasbeek Cornelis J A, Uitterhoeve Apollonia L J, van der Velden Jacobus, González Dionisio González, Stalpers Lukas J A
Department of Radiotherapy, Academic Medical Center, Amsterdam, The Netherlands.
Radiother Oncol. 2008 Nov;89(2):197-204. doi: 10.1016/j.radonc.2008.01.004. Epub 2008 Jan 30.
Tumor recurrence after surgery for cervical carcinoma is associated with high fatality and morbidity, forming a major therapeutic challenge. This paper presents our experience with treatment of this patient group by salvage radiotherapy with curative intent.
Thirty-five patients with a pelvic recurrence after hysterectomy received high-dose radiotherapy. A retrospective analysis of long-term outcome and prognostic factors was performed.
After a median follow-up period of 12.1 years, actuarial 2-,5- and 10-year overall survival rates were 66%, 43% and 33%; disease-free survival rates were 62%, 45% and 41%, respectively. Pelvic control rates at 2-,5- and 10-years were 77%, 69% and 62%. Unfavorable prognostic factors on univariate analysis for survival were: recurrence extending to the pelvic wall versus central recurrence, early recurrence after surgery, external boost versus brachytherapy boost, low total dose and high age. Only a brachytherapy boost and a long interval between surgery and recurrence were significant on multivariate analysis. Severe complications (> or = grade 3) were seen in 6 patients (17%; actuarial after 5 years, 21%).
Salvage radiotherapy for recurrent cervical carcinoma following surgery may result in 40-50% long-term disease-free survival and an acceptable risk of severe treatment complications, even in patient with recurrences extending to the pelvic wall.
宫颈癌手术后肿瘤复发与高死亡率和高发病率相关,构成了一项重大的治疗挑战。本文介绍了我们对这组患者进行根治性挽救性放疗的经验。
35例子宫切除术后盆腔复发的患者接受了高剂量放疗。对长期结局和预后因素进行了回顾性分析。
中位随访期为12.1年,精算2年、5年和10年总生存率分别为66%、4l%和33%;无病生存率分别为62%、45%和41%。2年、5年和10年的盆腔控制率分别为77%、69%和62%。单因素分析中生存的不良预后因素为:复发累及盆腔壁与中央复发、术后早期复发、外照射加量与近距离放疗加量、总剂量低和年龄大。多因素分析中仅近距离放疗加量以及手术与复发之间的间隔时间长具有显著意义。6例患者(17%;5年精算为21%)出现严重并发症(≥3级)。
即使对于复发累及盆腔壁的患者,宫颈癌手术后的挽救性放疗也可能带来40 - 50%的长期无病生存率以及可接受的严重治疗并发症风险。